Abstract
Summary HDAC inhibition has been shown to induce pharmacological BRCAness in cancer cells with proficient DNA repair activity. This provides a rationale for exploring combination treatments with HDAC and PARP inhibition in cancer types that are insensitive to single-agent PARP inhibitors. Here, we report the concept and characterization of a novel bifunctional PARP inhibitor (kt-3283) with dual activity towards PARP1/2 and HDAC enzymes in Ewing sarcoma cells. Compared to the FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models. The kt-3283-induced cytotoxicity was associated with a strong S and G2/M cell cycle arrest in the nanomolar concentration range and elevated DNA damage as assessed by γH2AX tracking and comet assays. In three-dimensional spheroid models of Ewing sarcoma, kt-3283 showed efficacy in lower concentrations than olaparib and vorinostat and kt-3283 inhibited colonization of Ewing sarcoma cells in an ex vivo lung metastasis model. In summary, our data indicate a potential benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma and provide proof-of-concept for a bi-functional single-molecule therapeutic strategy.
Competing Interest Statement
L.R., S.T., B.Z., J.J., F.G. hold stock options and are employees of Rakovina Therapeutics Inc. and J.B., D.B., J.L., W.S. and M.D., are co-founders and/or employees of Rakovina Therapeutics Inc. The remaining authors declare no conflict of interest.